Huasaibio raises $30M Series B to push solid-tumor TIL therapy into pivotal trials
What's the deal? Chinese biotech HuasaibioDealroom has a profile for this one. Try Dealroom → has closed a Series B round of nearly US$27.5M, led by Zhangjiang Science and Technology Investment. Guoxin Venture CapitalDealroom has a profile for this one. Try Dealroom →, Heda InvestmentDealroom has a profile for this one. Try Dealroom →, Hefei Industrial Investment Group Life Health Company, Feixi Industrial InvestmentDealroom has a profile for this one. Try Dealroom →, Hefei State Investment, and Hengze Capital joined the round.
What does it do? Huasaibio develops innovative cell therapies, focusing on tumour-infiltrating lymphocyte (TIL) treatments for solid tumours. The company is headquartered in Shanghai's Zhangjiang pharmaceutical hub.
What's the money for? The round will fund pivotal registrational trials for its TIL therapy and the build-out of a large-scale manufacturing system. Huasaibio says its core candidate, FAST-TIL, has entered a pivotal phase II and received a clinical trial clearance from the US Food and Drug Administration in September 2026.
Why now? The TIL field is gathering clearer clinical catalysts. Rival Junsai Bio's GC101 met its primary endpoint in a registrational phase II trial for advanced melanoma, with public reports showing progression-free survival ahead of chemotherapy; competitor GRIT is also advancing its TIL pipeline and new indications.
What could go wrong? TIL therapy remains in clinical development. The financing does not confirm efficacy or signal product approval, and Huasaibio still has to clear its pivotal trials.
The signal: The round matters less for its size than for what it buys — a seat in the race to validate and industrialise TIL therapy for solid tumours, a field where early rivals are now posting registrational data.
Read more: itjuzi.com
Image credit: Generated with Gemini
